Efficacy and Safety of the Soricle, a Class III Combination Device of Vagus Nerve Stimulation and Sound Stimulation, for Subjective Tinnitus Relief: A Prospective, Single-Center, Randomized, Double-Blind, Sham-Controlled, Exploratory Clinical Trial
| Registry | NCT07548320 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; randomized, parallel, masking: quadruple, treatment |
| Enrollment | 36 (Actual) |
| Sponsor | Neurive Co.,Ltd. (Industry) |
| Conditions | Tinnitus, Subjective Tinnitus |
| Interventions | Sham Device, tVNS Device, tVNS + Sound Stimulation Device (Device) |
| Dates | start 2025-03-10, primary completion 2025-09-08, completion 2025-09-08, first posted 2026-04-23, last updated 2026-04-23 |
| Locations | 1 site in South Korea |
Related Papers Related Patents Related Grants Related Experts
All trials for Tinnitus All trials for Subjective Tinnitus All trials of Sham Device All trials of tVNS Device
This study was conducted to evaluate the efficacy and safety of Soricle, a medical device combining transcutaneous vagus nerve stimulation and sound stimulation, in patients with subjective tinnitus.
Participants were randomly assigned to either the active treatment group or a sham control group in a double-blind manner. The device was used daily for 8 weeks.
The primary objective was to assess the improvement in tinnitus symptoms, and safety was evaluated throughout the study period.
This was a prospective, single-center, randomized, double-blind, sham-controlled exploratory clinical trial designed to evaluate the efficacy and safety of Soricle, a Class III medical device combining transcutaneous vagus nerve stimulation (tVNS) and sound stimulation, for the treatment of subjective tinnitus.
Participants diagnosed with subjective tinnitus were randomly assigned in a 1:1 ratio to either the active treatment group or the sham control group. The investigational device was applied daily for 8 weeks.
The primary objective of the study was to evaluate the improvement in tinnitus symptoms, and secondary objectives included additional efficacy assessments and safety evaluations. Safety was monitored throughout the study, including the assessment of adverse events.
The study was conducted in accordance with ICH-GCP guidelines and was approved by the Institutional Review Board. All participants provided written informed consent prior to participation.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Sham Comparator | Sham comparator | Device: Sham Device | Participants received a sham device identical in appearance to the active device but without delivering therapeutic stimulation. |
| tVNS Stimulation | Experimental | Device: tVNS Device | Participants received transcutaneous vagus nerve stimulation (tVNS) using the investigational device. |
| tVNS + Sound Stimulation | Experimental | Device: tVNS + Sound Stimulation Device | Participants received combined transcutaneous vagus nerve stimulation (tVNS) and sound stimulation using the investigational device. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Adults aged 18 years or older * Patients with subjective tinnitus * Able to understand and provide informed consent * Willing to comply with study procedures Exclusion Criteria: * Objective tinnitus * Severe hearing loss requiring immediate treatment * History of neurological or psychiatric disorders that may affect study outcomes * Use of other tinnitus treatments during the study period * Any condition that, in the investigator's judgment, may interfere with study participation
| Facility | City | Country | Status |
|---|---|---|---|
| Korea University Guro Hospital | Seoul | South Korea |